PSA Bouncing after Short Term Androgen Deprivation and 3D-Conformal Radiotherapy for Localized Prostate Adenocarcinoma and the Relationship with the Kinetics of Testosterone-Reference-Cited by-同舟云学术

PSA Bouncing after Short Term Androgen Deprivation and 3D-Conformal Radiotherapy for Localized Prostate Adenocarcinoma and the Relationship with the Kinetics of Testosterone

Published:2005-07 Issue:1 Volume:48 Page:40-45
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Akyol Fadil,Ozyigit Gokhan,Selek Ugur,Karabulut Erdem

Publisher

Elsevier BV

Subject

Urology

Reference27 articles.

1. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997; 37:1035–41.

2. Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer;Critz;J Urol,2000

3. Transient elevation of serum prostate-specific antigen following (125)I/(103)Pd brachytherapy for localized prostate cancer;Cavanagh;Semin Urol Oncol,2000

4. Patterns and fate of PSA bouncing following 3D-CRT;Hanlon;Int J Radiat Oncol Biol Phys,2001

5. Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer;Rosser;J Urol,2002

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genitourinary System Cancers;Basic Radiation Oncology;2022

2. Prostatakarzinom: Nachsorge;Uroonkologie;2022

3. Prostate-specific antigen (PSA) bounce following salvage radiotherapy to the prostate bed in a patient with prostate cancer post-prostatectomy;International Cancer Conference Journal;2020-06-27

4. Testosterone therapy does not increase the risks of prostate cancer recurrence or death after definitive treatment for localized disease;Prostate Cancer and Prostatic Diseases;2020-06-08

5. Prostate-specific antigen bounce after 125I-brachytherapy for prostate cancer is a favorable prognosticator in patients who are biochemical recurrence-free at 4 years and correlates with testosterone;Japanese Journal of Clinical Oncology;2019-10-28